Kaplan Fox Reminds Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Significant Losses to Seek a Leadership Role Before Deadline on September 28, 2026

Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the “Class Period”).

The complaint alleges that on July 27, 2026, before the market opened, the FDA released briefing documents ahead of its AdCom meeting for Capricor’s resubmitted Dermamiocel Biologics License Application (“BLA”). Further, the complaint alleges that according to the briefing documents, Capricor made changes to the pre-specified statistical analysis plan (“SAP”) and the final version “was not submitted to FDA for review prior to BLA submission and was not discussed and consequently not agreed upon.”

On July 27, 2026, Capricor’s stock price fell $12.70, or 64%, to close at $7 per share.